Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Central Nervous System Neoplasms | 68 | 2024 | 915 | 11.600 |
Why?
|
Brain Neoplasms | 169 | 2024 | 9025 | 7.130 |
Why?
|
Lymphoma | 46 | 2024 | 1898 | 6.890 |
Why?
|
Glioblastoma | 95 | 2024 | 3481 | 6.140 |
Why?
|
Lymphoma, Non-Hodgkin | 32 | 2021 | 1372 | 6.100 |
Why?
|
Glioma | 74 | 2024 | 3452 | 4.780 |
Why?
|
Angiogenesis Inhibitors | 32 | 2021 | 2047 | 2.690 |
Why?
|
Isocitrate Dehydrogenase | 19 | 2023 | 937 | 2.350 |
Why?
|
Methotrexate | 25 | 2023 | 1717 | 2.290 |
Why?
|
Quinazolines | 25 | 2017 | 1371 | 2.250 |
Why?
|
Antimetabolites, Antineoplastic | 17 | 2015 | 646 | 1.980 |
Why?
|
Dacarbazine | 22 | 2017 | 559 | 1.950 |
Why?
|
Neovascularization, Pathologic | 20 | 2017 | 2635 | 1.930 |
Why?
|
Neoplasm Recurrence, Local | 47 | 2024 | 9278 | 1.880 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 11 | 2022 | 1405 | 1.870 |
Why?
|
Antineoplastic Agents, Alkylating | 21 | 2020 | 617 | 1.860 |
Why?
|
Antineoplastic Agents | 54 | 2020 | 13630 | 1.810 |
Why?
|
Nervous System Neoplasms | 6 | 2018 | 91 | 1.710 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 34 | 2024 | 11732 | 1.650 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 15 | 2017 | 664 | 1.370 |
Why?
|
Glutarates | 10 | 2021 | 243 | 1.350 |
Why?
|
Combined Modality Therapy | 35 | 2024 | 8519 | 1.180 |
Why?
|
Cranial Irradiation | 8 | 2021 | 390 | 1.180 |
Why?
|
Neurotoxicity Syndromes | 6 | 2023 | 301 | 1.050 |
Why?
|
Vascular Endothelial Growth Factor A | 16 | 2018 | 3493 | 1.050 |
Why?
|
Paraneoplastic Syndromes | 5 | 2022 | 155 | 1.020 |
Why?
|
Vascular Endothelial Growth Factors | 3 | 2013 | 748 | 0.990 |
Why?
|
Salvage Therapy | 8 | 2019 | 1264 | 0.920 |
Why?
|
Stem Cell Transplantation | 7 | 2018 | 1600 | 0.920 |
Why?
|
Mutation | 45 | 2024 | 30006 | 0.830 |
Why?
|
Magnetic Resonance Spectroscopy | 9 | 2024 | 3770 | 0.820 |
Why?
|
Radiotherapy | 10 | 2019 | 1498 | 0.790 |
Why?
|
Humans | 311 | 2024 | 761098 | 0.780 |
Why?
|
Capillary Permeability | 2 | 2019 | 773 | 0.760 |
Why?
|
Epidural Neoplasms | 3 | 2016 | 24 | 0.740 |
Why?
|
Disease-Free Survival | 34 | 2020 | 6817 | 0.740 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2019 | 696 | 0.730 |
Why?
|
Prognosis | 46 | 2021 | 29672 | 0.690 |
Why?
|
Meningeal Neoplasms | 11 | 2017 | 1246 | 0.640 |
Why?
|
Protein Kinase Inhibitors | 11 | 2024 | 5662 | 0.630 |
Why?
|
Brain Edema | 6 | 2009 | 604 | 0.620 |
Why?
|
Brain | 31 | 2024 | 27097 | 0.590 |
Why?
|
Maximum Tolerated Dose | 10 | 2020 | 883 | 0.540 |
Why?
|
Myeloid Differentiation Factor 88 | 3 | 2021 | 583 | 0.540 |
Why?
|
Nervous System Diseases | 4 | 2022 | 1663 | 0.540 |
Why?
|
Magnetic Resonance Imaging | 56 | 2021 | 36418 | 0.530 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 183 | 0.530 |
Why?
|
Transplantation, Autologous | 8 | 2024 | 2112 | 0.530 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2024 | 5667 | 0.510 |
Why?
|
Brain Diseases | 3 | 2019 | 1546 | 0.500 |
Why?
|
Middle Aged | 123 | 2024 | 220835 | 0.490 |
Why?
|
Critical Pathways | 1 | 2019 | 475 | 0.490 |
Why?
|
Aged | 103 | 2024 | 169266 | 0.490 |
Why?
|
Cytarabine | 8 | 2024 | 697 | 0.490 |
Why?
|
Survival Rate | 26 | 2020 | 12727 | 0.470 |
Why?
|
Neoplasm Proteins | 6 | 2021 | 3594 | 0.460 |
Why?
|
Male | 141 | 2024 | 360675 | 0.460 |
Why?
|
Eye Neoplasms | 4 | 2008 | 307 | 0.450 |
Why?
|
Blood-Brain Barrier | 7 | 2019 | 1027 | 0.450 |
Why?
|
Nose Neoplasms | 1 | 2016 | 249 | 0.440 |
Why?
|
Astrocytoma | 6 | 2013 | 774 | 0.440 |
Why?
|
Female | 144 | 2024 | 392458 | 0.440 |
Why?
|
Biostatistics | 1 | 2015 | 164 | 0.430 |
Why?
|
Adult | 114 | 2024 | 221083 | 0.430 |
Why?
|
Clinical Trials as Topic | 17 | 2023 | 8000 | 0.430 |
Why?
|
Central Nervous System | 7 | 2022 | 1333 | 0.420 |
Why?
|
Treatment Outcome | 53 | 2024 | 64670 | 0.420 |
Why?
|
Parietal Lobe | 2 | 2016 | 852 | 0.420 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 694 | 0.400 |
Why?
|
Enzyme Inhibitors | 4 | 2018 | 3700 | 0.400 |
Why?
|
Pyridines | 9 | 2021 | 2872 | 0.400 |
Why?
|
Cranial Nerves | 1 | 2012 | 98 | 0.400 |
Why?
|
Lymphoproliferative Disorders | 1 | 2016 | 530 | 0.390 |
Why?
|
Vitreous Body | 3 | 2021 | 399 | 0.380 |
Why?
|
Polyneuropathies | 1 | 2012 | 137 | 0.370 |
Why?
|
DNA Modification Methylases | 6 | 2013 | 210 | 0.350 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 2 | 2009 | 83 | 0.350 |
Why?
|
Disease Progression | 28 | 2019 | 13506 | 0.340 |
Why?
|
Camptothecin | 4 | 2009 | 591 | 0.340 |
Why?
|
Immunologic Factors | 1 | 2019 | 1589 | 0.330 |
Why?
|
DNA Repair Enzymes | 6 | 2013 | 346 | 0.330 |
Why?
|
Headache | 3 | 2015 | 1255 | 0.320 |
Why?
|
Neoplasms | 11 | 2023 | 22125 | 0.320 |
Why?
|
Lymphoma, T-Cell | 3 | 2019 | 303 | 0.320 |
Why?
|
Diffusion Magnetic Resonance Imaging | 4 | 2018 | 2787 | 0.320 |
Why?
|
Peripheral Nerves | 1 | 2012 | 479 | 0.310 |
Why?
|
Lymphoma, B-Cell | 4 | 2006 | 938 | 0.300 |
Why?
|
Oligodendroglioma | 4 | 2019 | 278 | 0.300 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4340 | 0.300 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2018 | 5300 | 0.290 |
Why?
|
Gene Amplification | 5 | 2016 | 1084 | 0.290 |
Why?
|
Phthalazines | 1 | 2010 | 383 | 0.290 |
Why?
|
Piperazines | 2 | 2021 | 2522 | 0.290 |
Why?
|
Disease Management | 5 | 2019 | 2508 | 0.290 |
Why?
|
Hypertensive Encephalopathy | 1 | 2007 | 9 | 0.290 |
Why?
|
Aged, 80 and over | 37 | 2024 | 58946 | 0.290 |
Why?
|
Piperidines | 5 | 2019 | 1656 | 0.290 |
Why?
|
Topotecan | 1 | 2007 | 131 | 0.290 |
Why?
|
Drug Administration Schedule | 9 | 2018 | 4849 | 0.280 |
Why?
|
Diagnostic Imaging | 5 | 2014 | 3535 | 0.270 |
Why?
|
Histones | 6 | 2024 | 2570 | 0.270 |
Why?
|
Receptors, Dopamine D2 | 2 | 2019 | 485 | 0.270 |
Why?
|
Young Adult | 36 | 2024 | 59199 | 0.270 |
Why?
|
Burkitt Lymphoma | 2 | 2019 | 335 | 0.270 |
Why?
|
Hodgkin Disease | 2 | 2008 | 1378 | 0.260 |
Why?
|
Morpholines | 2 | 2019 | 581 | 0.250 |
Why?
|
Hypoglossal Nerve | 2 | 1997 | 107 | 0.250 |
Why?
|
Nerve Sheath Neoplasms | 2 | 2005 | 170 | 0.250 |
Why?
|
Neoplasm Staging | 13 | 2020 | 11118 | 0.250 |
Why?
|
Tumor Suppressor Proteins | 7 | 2017 | 2802 | 0.250 |
Why?
|
Blood Vessels | 4 | 2014 | 1111 | 0.250 |
Why?
|
Ribonuclease, Pancreatic | 2 | 2016 | 112 | 0.250 |
Why?
|
Survival Analysis | 17 | 2023 | 10083 | 0.250 |
Why?
|
Positron-Emission Tomography | 4 | 2021 | 6585 | 0.250 |
Why?
|
Paralysis | 2 | 1997 | 250 | 0.250 |
Why?
|
Radiation Injuries | 3 | 2019 | 1191 | 0.250 |
Why?
|
Retinal Neoplasms | 2 | 2021 | 148 | 0.240 |
Why?
|
Image Processing, Computer-Assisted | 8 | 2019 | 9001 | 0.240 |
Why?
|
Kaplan-Meier Estimate | 16 | 2020 | 6482 | 0.240 |
Why?
|
Aminopyridines | 2 | 2019 | 573 | 0.240 |
Why?
|
Bayes Theorem | 5 | 2023 | 2327 | 0.240 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 899 | 0.240 |
Why?
|
Antibodies, Neoplasm | 2 | 2016 | 282 | 0.240 |
Why?
|
Leukemia, Plasma Cell | 1 | 2004 | 46 | 0.240 |
Why?
|
Tumor Microenvironment | 8 | 2023 | 3869 | 0.230 |
Why?
|
Plasmacytoma | 1 | 2004 | 170 | 0.230 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2020 | 10755 | 0.230 |
Why?
|
Oligodendroglia | 2 | 2018 | 538 | 0.230 |
Why?
|
Snake Venoms | 2 | 2015 | 38 | 0.230 |
Why?
|
Xenograft Model Antitumor Assays | 11 | 2020 | 3591 | 0.220 |
Why?
|
Cyclophosphamide | 7 | 2019 | 2219 | 0.220 |
Why?
|
Diagnosis, Differential | 10 | 2019 | 12975 | 0.220 |
Why?
|
Neoplasm Metastasis | 5 | 2020 | 4908 | 0.220 |
Why?
|
Pyrimidines | 6 | 2024 | 3026 | 0.210 |
Why?
|
Imaging, Three-Dimensional | 5 | 2024 | 4060 | 0.210 |
Why?
|
Hematologic Neoplasms | 1 | 2015 | 1895 | 0.210 |
Why?
|
Medical Oncology | 3 | 2018 | 2316 | 0.210 |
Why?
|
Tomography, X-Ray Computed | 9 | 2022 | 20600 | 0.210 |
Why?
|
Immunotherapy, Adoptive | 3 | 2023 | 1468 | 0.210 |
Why?
|
Meningitis | 1 | 2004 | 217 | 0.210 |
Why?
|
Receptors, Dopamine D5 | 2 | 2020 | 32 | 0.210 |
Why?
|
Preventive Medicine | 1 | 2004 | 245 | 0.210 |
Why?
|
Meningioma | 3 | 2017 | 1216 | 0.200 |
Why?
|
Neoplastic Stem Cells | 3 | 2017 | 1348 | 0.200 |
Why?
|
DNA Methylation | 6 | 2019 | 4386 | 0.200 |
Why?
|
Paraproteinemias | 1 | 2004 | 250 | 0.200 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2019 | 3512 | 0.200 |
Why?
|
Genetic Predisposition to Disease | 3 | 2023 | 17889 | 0.200 |
Why?
|
Oxygen | 1 | 2013 | 4226 | 0.200 |
Why?
|
Thalidomide | 5 | 2019 | 885 | 0.200 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 3 | 2017 | 83 | 0.190 |
Why?
|
Molecular Targeted Therapy | 6 | 2019 | 2813 | 0.190 |
Why?
|
Chromosomes, Human, Pair 10 | 3 | 2009 | 277 | 0.190 |
Why?
|
Imidazoles | 4 | 2020 | 1173 | 0.190 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.180 |
Why?
|
Inositol | 1 | 2021 | 215 | 0.180 |
Why?
|
Neoplasms, Experimental | 2 | 2016 | 1225 | 0.180 |
Why?
|
Terminology as Topic | 2 | 2018 | 1528 | 0.180 |
Why?
|
Spinal Cord Neoplasms | 2 | 2014 | 261 | 0.180 |
Why?
|
Stress, Physiological | 2 | 2019 | 1406 | 0.180 |
Why?
|
Recurrence | 6 | 2012 | 8456 | 0.180 |
Why?
|
Cell Line, Tumor | 13 | 2019 | 16947 | 0.180 |
Why?
|
Pyrazoles | 5 | 2019 | 2010 | 0.180 |
Why?
|
Hydroxamic Acids | 2 | 2015 | 479 | 0.180 |
Why?
|
Hexokinase | 1 | 2020 | 124 | 0.170 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2015 | 1784 | 0.170 |
Why?
|
Quinolines | 2 | 2016 | 764 | 0.170 |
Why?
|
Follow-Up Studies | 21 | 2019 | 39121 | 0.170 |
Why?
|
Echo-Planar Imaging | 1 | 2024 | 663 | 0.170 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2013 | 628 | 0.170 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2019 | 2057 | 0.170 |
Why?
|
Corpus Callosum | 1 | 2005 | 750 | 0.170 |
Why?
|
Meningeal Carcinomatosis | 1 | 2020 | 63 | 0.170 |
Why?
|
Gene Deletion | 2 | 2005 | 2656 | 0.170 |
Why?
|
Oncolytic Viruses | 1 | 2023 | 344 | 0.170 |
Why?
|
Transcription Factor RelA | 1 | 2020 | 254 | 0.170 |
Why?
|
Chromosomes, Human, Pair 19 | 3 | 2005 | 350 | 0.160 |
Why?
|
Consensus Development Conferences as Topic | 2 | 2017 | 168 | 0.160 |
Why?
|
Tissue Distribution | 3 | 2017 | 2262 | 0.160 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2018 | 1331 | 0.160 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 94 | 0.160 |
Why?
|
Biopsy | 6 | 2019 | 6781 | 0.160 |
Why?
|
Anticonvulsants | 7 | 2010 | 1911 | 0.160 |
Why?
|
Vincristine | 2 | 2019 | 1036 | 0.160 |
Why?
|
Drug Delivery Systems | 3 | 2018 | 2223 | 0.160 |
Why?
|
Retrospective Studies | 31 | 2023 | 80673 | 0.150 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2018 | 42 | 0.150 |
Why?
|
Neurosciences | 1 | 2023 | 369 | 0.150 |
Why?
|
Transplantation Conditioning | 3 | 2017 | 1591 | 0.150 |
Why?
|
Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
Adolescent | 22 | 2024 | 88271 | 0.150 |
Why?
|
Chromosomes, Human, Pair 1 | 3 | 2005 | 638 | 0.150 |
Why?
|
Immunohistochemistry | 11 | 2018 | 11066 | 0.150 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2019 | 126 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 348 | 0.150 |
Why?
|
Animals | 31 | 2020 | 168083 | 0.150 |
Why?
|
Herpesvirus 1, Human | 1 | 2023 | 739 | 0.150 |
Why?
|
Endothelial Cells | 3 | 2023 | 3550 | 0.150 |
Why?
|
Oncolytic Virotherapy | 1 | 2023 | 515 | 0.150 |
Why?
|
NAD | 3 | 2017 | 611 | 0.150 |
Why?
|
Signal Transduction | 14 | 2020 | 23415 | 0.150 |
Why?
|
Lomustine | 2 | 2017 | 60 | 0.150 |
Why?
|
Indoles | 3 | 2015 | 1830 | 0.150 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 223 | 0.150 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2014 | 1520 | 0.150 |
Why?
|
Polymerase Chain Reaction | 6 | 2013 | 6067 | 0.150 |
Why?
|
Ketoglutarate Dehydrogenase Complex | 1 | 2017 | 21 | 0.150 |
Why?
|
Guanidines | 1 | 2018 | 194 | 0.150 |
Why?
|
Radiation Injuries, Experimental | 1 | 2017 | 88 | 0.140 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2016 | 1655 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 8529 | 0.140 |
Why?
|
Macrophages | 4 | 2017 | 5754 | 0.140 |
Why?
|
Karnofsky Performance Status | 3 | 2015 | 166 | 0.140 |
Why?
|
Chorea | 1 | 1998 | 79 | 0.140 |
Why?
|
Tongue | 2 | 1997 | 403 | 0.140 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2018 | 943 | 0.140 |
Why?
|
Mental Status Schedule | 2 | 2011 | 314 | 0.140 |
Why?
|
Models, Biological | 5 | 2016 | 9455 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 6 | 2014 | 2508 | 0.140 |
Why?
|
Hydroxyurea | 1 | 2018 | 284 | 0.140 |
Why?
|
Lung Neoplasms | 4 | 2024 | 13382 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2004 | 2914 | 0.130 |
Why?
|
Mice, SCID | 5 | 2020 | 2621 | 0.130 |
Why?
|
Tongue Diseases | 1 | 1996 | 68 | 0.130 |
Why?
|
NADP | 1 | 2017 | 227 | 0.130 |
Why?
|
DNA-Binding Proteins | 5 | 2008 | 9566 | 0.130 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2020 | 10213 | 0.130 |
Why?
|
Gene Expression Profiling | 7 | 2015 | 9416 | 0.130 |
Why?
|
Tumor Escape | 1 | 2019 | 371 | 0.130 |
Why?
|
Muscle Weakness | 2 | 2015 | 412 | 0.130 |
Why?
|
Thiotepa | 4 | 2017 | 66 | 0.130 |
Why?
|
Phenylurea Compounds | 2 | 2016 | 529 | 0.130 |
Why?
|
Lithium | 1 | 2019 | 596 | 0.130 |
Why?
|
Cognition Disorders | 4 | 2016 | 3974 | 0.130 |
Why?
|
Blood Volume Determination | 1 | 2015 | 41 | 0.130 |
Why?
|
Procarbazine | 2 | 2006 | 172 | 0.130 |
Why?
|
Magnetic Resonance Angiography | 2 | 2013 | 1432 | 0.130 |
Why?
|
Toll-Like Receptors | 1 | 2019 | 575 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2019 | 2455 | 0.120 |
Why?
|
Postoperative Care | 2 | 2019 | 1469 | 0.120 |
Why?
|
Testicular Neoplasms | 1 | 2001 | 800 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2016 | 2820 | 0.120 |
Why?
|
Prospective Studies | 13 | 2024 | 54419 | 0.120 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2017 | 629 | 0.120 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2528 | 0.120 |
Why?
|
Algorithms | 6 | 2024 | 14023 | 0.120 |
Why?
|
Administration, Oral | 4 | 2017 | 4014 | 0.120 |
Why?
|
Rhabdoid Tumor | 1 | 2017 | 210 | 0.120 |
Why?
|
Oncogenes | 2 | 2018 | 1220 | 0.120 |
Why?
|
Neoadjuvant Therapy | 3 | 2019 | 2827 | 0.120 |
Why?
|
Leukemia | 2 | 2015 | 1518 | 0.120 |
Why?
|
Hemangioblastoma | 1 | 2014 | 62 | 0.120 |
Why?
|
Busulfan | 4 | 2017 | 258 | 0.120 |
Why?
|
Gene Dosage | 1 | 2019 | 1217 | 0.120 |
Why?
|
B-Lymphocytes | 2 | 2021 | 4744 | 0.120 |
Why?
|
Loss of Heterozygosity | 2 | 2009 | 663 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 546 | 0.110 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2016 | 714 | 0.110 |
Why?
|
Endpoint Determination | 2 | 2008 | 590 | 0.110 |
Why?
|
Wnt Proteins | 1 | 2018 | 719 | 0.110 |
Why?
|
Neurosurgical Procedures | 3 | 2019 | 2067 | 0.110 |
Why?
|
Etoposide | 2 | 2013 | 634 | 0.110 |
Why?
|
NF-kappa B | 2 | 2020 | 2475 | 0.110 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2017 | 455 | 0.110 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2020 | 3367 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2019 | 858 | 0.110 |
Why?
|
Receptors, CXCR4 | 1 | 2018 | 727 | 0.110 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 196 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3803 | 0.110 |
Why?
|
Vesicular Transport Proteins | 1 | 2016 | 374 | 0.110 |
Why?
|
Age Factors | 5 | 2019 | 18385 | 0.110 |
Why?
|
Drug Antagonism | 1 | 2013 | 51 | 0.110 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 1008 | 0.110 |
Why?
|
Adenine | 1 | 2019 | 986 | 0.110 |
Why?
|
Tumor Cells, Cultured | 5 | 2019 | 6123 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 305 | 0.110 |
Why?
|
Fatal Outcome | 3 | 2012 | 1837 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2549 | 0.100 |
Why?
|
Cohort Studies | 14 | 2022 | 41486 | 0.100 |
Why?
|
Polyradiculopathy | 1 | 2012 | 23 | 0.100 |
Why?
|
Somatostatin | 1 | 2014 | 447 | 0.100 |
Why?
|
Radiosurgery | 2 | 2020 | 1339 | 0.100 |
Why?
|
International Agencies | 1 | 2013 | 244 | 0.100 |
Why?
|
Muscular Diseases | 1 | 1997 | 552 | 0.100 |
Why?
|
Natural Killer T-Cells | 1 | 2016 | 322 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 890 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 3 | 2017 | 3725 | 0.100 |
Why?
|
Contrast Media | 4 | 2018 | 5311 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2013 | 2054 | 0.100 |
Why?
|
Injections, Spinal | 4 | 2007 | 317 | 0.100 |
Why?
|
src-Family Kinases | 1 | 2014 | 535 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2021 | 2567 | 0.100 |
Why?
|
Peripheral Nervous System Neoplasms | 2 | 2005 | 133 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2018 | 961 | 0.100 |
Why?
|
Likelihood Functions | 1 | 2015 | 991 | 0.100 |
Why?
|
Dexamethasone | 2 | 2011 | 1945 | 0.100 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2011 | 326 | 0.100 |
Why?
|
Gene Expression | 4 | 2018 | 7567 | 0.100 |
Why?
|
Palliative Care | 1 | 2006 | 3593 | 0.100 |
Why?
|
Statistics, Nonparametric | 2 | 2014 | 2855 | 0.090 |
Why?
|
Genotype | 4 | 2023 | 12983 | 0.090 |
Why?
|
Nausea | 3 | 2020 | 679 | 0.090 |
Why?
|
Mice | 17 | 2020 | 81324 | 0.090 |
Why?
|
DNA Replication | 1 | 2018 | 1415 | 0.090 |
Why?
|
Fixatives | 1 | 2010 | 90 | 0.090 |
Why?
|
Benzenesulfonates | 1 | 2011 | 166 | 0.090 |
Why?
|
Interferon Inducers | 1 | 2010 | 25 | 0.090 |
Why?
|
Chromosomes, Artificial, Bacterial | 1 | 2010 | 123 | 0.090 |
Why?
|
DNA, Neoplasm | 3 | 2024 | 1743 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 987 | 0.090 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2014 | 736 | 0.090 |
Why?
|
Carboxymethylcellulose Sodium | 1 | 2010 | 38 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 1 | 2003 | 4510 | 0.090 |
Why?
|
Mice, Nude | 4 | 2020 | 3604 | 0.090 |
Why?
|
Epothilones | 1 | 2010 | 42 | 0.090 |
Why?
|
Cell Hypoxia | 1 | 2013 | 656 | 0.090 |
Why?
|
Leukemic Infiltration | 1 | 2010 | 47 | 0.090 |
Why?
|
Poly I-C | 1 | 2010 | 112 | 0.090 |
Why?
|
Polylysine | 1 | 2010 | 131 | 0.090 |
Why?
|
Bone Marrow Cells | 1 | 2017 | 2410 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 176 | 0.090 |
Why?
|
Remission Induction | 3 | 2017 | 2392 | 0.090 |
Why?
|
Neurology | 1 | 2018 | 784 | 0.080 |
Why?
|
Bone Marrow Transplantation | 1 | 2017 | 2692 | 0.080 |
Why?
|
Up-Regulation | 1 | 2019 | 4111 | 0.080 |
Why?
|
Cerebellar Neoplasms | 1 | 2014 | 586 | 0.080 |
Why?
|
Dimethylnitrosamine | 1 | 2009 | 17 | 0.080 |
Why?
|
Paraffin Embedding | 1 | 2010 | 302 | 0.080 |
Why?
|
Necrosis | 4 | 2019 | 1611 | 0.080 |
Why?
|
Methylation | 1 | 2012 | 1070 | 0.080 |
Why?
|
Nitriles | 1 | 2014 | 971 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2019 | 2864 | 0.080 |
Why?
|
Nitrosamines | 1 | 2009 | 87 | 0.080 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2016 | 614 | 0.080 |
Why?
|
Radiography | 4 | 2014 | 6975 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1073 | 0.080 |
Why?
|
Nitrites | 1 | 2009 | 156 | 0.080 |
Why?
|
Formaldehyde | 1 | 2010 | 357 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 6919 | 0.080 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 9185 | 0.080 |
Why?
|
Melanoma | 2 | 2019 | 5694 | 0.080 |
Why?
|
Quality of Life | 9 | 2019 | 13362 | 0.080 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 178 | 0.080 |
Why?
|
Regeneration | 1 | 2017 | 1505 | 0.080 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1624 | 0.080 |
Why?
|
World Health Organization | 3 | 2021 | 1321 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2022 | 3634 | 0.080 |
Why?
|
Hematologic Tests | 1 | 2009 | 239 | 0.080 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1038 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2019 | 5809 | 0.070 |
Why?
|
Pyrroles | 1 | 2014 | 1125 | 0.070 |
Why?
|
Head | 1 | 2014 | 922 | 0.070 |
Why?
|
Nitrates | 1 | 2009 | 260 | 0.070 |
Why?
|
Myeloid Cells | 1 | 2013 | 821 | 0.070 |
Why?
|
Point Mutation | 1 | 2013 | 1593 | 0.070 |
Why?
|
Research Design | 3 | 2013 | 6178 | 0.070 |
Why?
|
Image Enhancement | 1 | 2018 | 2888 | 0.070 |
Why?
|
Patient Selection | 3 | 2016 | 4245 | 0.070 |
Why?
|
Consensus | 4 | 2021 | 3133 | 0.070 |
Why?
|
Sirolimus | 1 | 2014 | 1540 | 0.070 |
Why?
|
Ependymoma | 1 | 2010 | 320 | 0.070 |
Why?
|
Phenytoin | 1 | 2008 | 190 | 0.070 |
Why?
|
Radiotherapy, Conformal | 1 | 2010 | 548 | 0.070 |
Why?
|
Immunotherapy | 2 | 2023 | 4642 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 558 | 0.070 |
Why?
|
Neurofibromatosis 2 | 1 | 2010 | 383 | 0.070 |
Why?
|
Transcription Factors | 3 | 2020 | 12096 | 0.070 |
Why?
|
Lymphoma, Follicular | 1 | 2011 | 457 | 0.070 |
Why?
|
Multiple Myeloma | 1 | 2004 | 5145 | 0.070 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15308 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 1998 | 4538 | 0.070 |
Why?
|
Neuroma, Acoustic | 1 | 2010 | 458 | 0.070 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 2 | 2006 | 265 | 0.070 |
Why?
|
Computer Simulation | 3 | 2016 | 6225 | 0.070 |
Why?
|
Remission, Spontaneous | 1 | 2007 | 384 | 0.070 |
Why?
|
Meat | 1 | 2009 | 584 | 0.070 |
Why?
|
Gene Silencing | 2 | 2014 | 1496 | 0.070 |
Why?
|
Genes, p53 | 2 | 2005 | 713 | 0.070 |
Why?
|
Random Allocation | 2 | 2023 | 2393 | 0.070 |
Why?
|
Bacterial Infections | 2 | 2017 | 1390 | 0.070 |
Why?
|
Time | 1 | 2008 | 545 | 0.070 |
Why?
|
Child | 11 | 2024 | 80134 | 0.060 |
Why?
|
Child, Preschool | 7 | 2024 | 42217 | 0.060 |
Why?
|
Hospitals | 1 | 2019 | 3881 | 0.060 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2004 | 709 | 0.060 |
Why?
|
Chemokines, CXC | 1 | 2007 | 416 | 0.060 |
Why?
|
Edema | 1 | 2009 | 765 | 0.060 |
Why?
|
Gene Frequency | 2 | 2020 | 3603 | 0.060 |
Why?
|
Hyperventilation | 1 | 2005 | 78 | 0.060 |
Why?
|
Genes, p16 | 1 | 2005 | 160 | 0.060 |
Why?
|
Cooperative Behavior | 2 | 2010 | 1505 | 0.060 |
Why?
|
Vision Disorders | 1 | 2012 | 1088 | 0.060 |
Why?
|
Immunocompetence | 1 | 2005 | 138 | 0.060 |
Why?
|
Chemokine CXCL12 | 1 | 2007 | 454 | 0.060 |
Why?
|
Incidence | 3 | 2019 | 21357 | 0.060 |
Why?
|
Drug Interactions | 3 | 2008 | 1417 | 0.060 |
Why?
|
Enzyme Activation | 3 | 2019 | 3577 | 0.060 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2005 | 134 | 0.060 |
Why?
|
Cryoglobulinemia | 1 | 2004 | 84 | 0.060 |
Why?
|
Glycolysis | 2 | 2020 | 836 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 3591 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2012 | 1051 | 0.060 |
Why?
|
Kidney Function Tests | 1 | 2006 | 680 | 0.060 |
Why?
|
Time Factors | 6 | 2019 | 39953 | 0.060 |
Why?
|
Glucose | 1 | 2016 | 4341 | 0.060 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 734 | 0.060 |
Why?
|
Immunophenotyping | 1 | 2009 | 1867 | 0.060 |
Why?
|
Sulfonamides | 3 | 2008 | 1977 | 0.060 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2004 | 326 | 0.060 |
Why?
|
Immunoenzyme Techniques | 3 | 2013 | 1703 | 0.060 |
Why?
|
Phantoms, Imaging | 3 | 2020 | 2515 | 0.060 |
Why?
|
Neuropsychological Tests | 3 | 2017 | 7043 | 0.050 |
Why?
|
Genomics | 2 | 2020 | 5828 | 0.050 |
Why?
|
Syndecans | 1 | 2003 | 75 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4853 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2016 | 4372 | 0.050 |
Why?
|
Cell Proliferation | 5 | 2018 | 10421 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2018 | 2010 | 0.050 |
Why?
|
Herpesvirus 4, Human | 1 | 2009 | 1076 | 0.050 |
Why?
|
Meninges | 1 | 2005 | 197 | 0.050 |
Why?
|
Perfusion | 2 | 2019 | 1390 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2020 | 858 | 0.050 |
Why?
|
Brain Stem Neoplasms | 1 | 2005 | 189 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 190 | 0.050 |
Why?
|
STAT3 Transcription Factor | 1 | 2006 | 872 | 0.050 |
Why?
|
Cell Movement | 2 | 2017 | 5195 | 0.050 |
Why?
|
Antineoplastic Protocols | 2 | 2015 | 48 | 0.050 |
Why?
|
Syndecan-1 | 1 | 2003 | 163 | 0.050 |
Why?
|
Stereotaxic Techniques | 1 | 2005 | 555 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2016 | 4574 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 276 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2014 | 2217 | 0.050 |
Why?
|
DNA Mismatch Repair | 2 | 2020 | 428 | 0.050 |
Why?
|
Phenotype | 5 | 2020 | 16572 | 0.050 |
Why?
|
Disease Models, Animal | 5 | 2019 | 18217 | 0.050 |
Why?
|
Seizures | 3 | 2008 | 2965 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7400 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2006 | 1240 | 0.050 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 4109 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2020 | 22157 | 0.050 |
Why?
|
Interferon Regulatory Factors | 1 | 2003 | 261 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4813 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2018 | 566 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2023 | 20120 | 0.050 |
Why?
|
Flow Cytometry | 2 | 2013 | 5870 | 0.050 |
Why?
|
Biological Availability | 1 | 2001 | 389 | 0.050 |
Why?
|
Antibodies | 1 | 2009 | 2415 | 0.050 |
Why?
|
Models, Genetic | 2 | 2009 | 3430 | 0.050 |
Why?
|
Movement Disorders | 1 | 2005 | 459 | 0.050 |
Why?
|
Fibroblast Growth Factors | 1 | 2007 | 863 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2010 | 1878 | 0.050 |
Why?
|
Creatinine | 1 | 2006 | 1897 | 0.050 |
Why?
|
Cytokines | 1 | 2015 | 7386 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74219 | 0.040 |
Why?
|
Logistic Models | 1 | 2015 | 13254 | 0.040 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.040 |
Why?
|
Microcirculation | 2 | 2016 | 1280 | 0.040 |
Why?
|
Pilot Projects | 2 | 2011 | 8639 | 0.040 |
Why?
|
Vomiting | 2 | 2020 | 651 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2004 | 1535 | 0.040 |
Why?
|
Proportional Hazards Models | 5 | 2014 | 12467 | 0.040 |
Why?
|
Neprilysin | 1 | 2003 | 478 | 0.040 |
Why?
|
Chromosome Deletion | 1 | 2005 | 1386 | 0.040 |
Why?
|
Cerebrospinal Fluid Proteins | 1 | 2020 | 71 | 0.040 |
Why?
|
Matrix Metalloproteinase 13 | 1 | 2020 | 102 | 0.040 |
Why?
|
International Cooperation | 4 | 2010 | 1423 | 0.040 |
Why?
|
Proteoglycans | 1 | 2003 | 803 | 0.040 |
Why?
|
Lactic Acid | 1 | 2005 | 1139 | 0.040 |
Why?
|
Meningitis, Aseptic | 1 | 1999 | 59 | 0.040 |
Why?
|
Viral Matrix Proteins | 1 | 2020 | 193 | 0.040 |
Why?
|
Treatment Failure | 2 | 2021 | 2643 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2004 | 1381 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2022 | 329 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2001 | 1376 | 0.040 |
Why?
|
Staphylococcal Protein A | 1 | 1998 | 39 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7873 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 424 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20981 | 0.040 |
Why?
|
Genetic Markers | 1 | 2005 | 2599 | 0.040 |
Why?
|
Genes, myc | 1 | 2020 | 390 | 0.040 |
Why?
|
Aging | 1 | 2018 | 8701 | 0.040 |
Why?
|
Guidelines as Topic | 1 | 2005 | 1386 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2020 | 4250 | 0.040 |
Why?
|
Odds Ratio | 1 | 2011 | 9648 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14607 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1895 | 0.040 |
Why?
|
Adsorption | 1 | 1998 | 197 | 0.040 |
Why?
|
Immune Sera | 1 | 1999 | 605 | 0.040 |
Why?
|
Pyridones | 1 | 2024 | 809 | 0.040 |
Why?
|
Myoclonus | 1 | 1998 | 107 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2004 | 2927 | 0.040 |
Why?
|
Cell Survival | 2 | 2018 | 5776 | 0.040 |
Why?
|
Dura Mater | 1 | 2020 | 290 | 0.040 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2018 | 109 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2018 | 66 | 0.040 |
Why?
|
Age Distribution | 1 | 2004 | 2873 | 0.040 |
Why?
|
Inhibitor of Differentiation Protein 1 | 1 | 2017 | 47 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 782 | 0.040 |
Why?
|
Immune System | 1 | 2023 | 792 | 0.040 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2016 | 801 | 0.040 |
Why?
|
Biological Therapy | 1 | 1999 | 139 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2019 | 2452 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 559 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 247 | 0.040 |
Why?
|
Glycoproteins | 1 | 2005 | 2203 | 0.040 |
Why?
|
Benchmarking | 1 | 2024 | 1045 | 0.040 |
Why?
|
Cognition | 1 | 2015 | 6987 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 849 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 245 | 0.040 |
Why?
|
Quinazolinones | 1 | 2019 | 221 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2006 | 1304 | 0.040 |
Why?
|
Automation | 1 | 2019 | 585 | 0.030 |
Why?
|
Apoptosis | 3 | 2018 | 9478 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2018 | 270 | 0.030 |
Why?
|
Respiratory Muscles | 1 | 1997 | 142 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2005 | 6224 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2020 | 4739 | 0.030 |
Why?
|
Cranial Nerve Diseases | 1 | 1997 | 110 | 0.030 |
Why?
|
Folic Acid | 1 | 2023 | 1323 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2017 | 404 | 0.030 |
Why?
|
4-1BB Ligand | 1 | 2016 | 29 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1404 | 0.030 |
Why?
|
Sciatic Nerve | 1 | 2000 | 618 | 0.030 |
Why?
|
Pentosyltransferases | 1 | 2015 | 62 | 0.030 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 368 | 0.030 |
Why?
|
Mutagenesis | 1 | 2020 | 1227 | 0.030 |
Why?
|
OX40 Ligand | 1 | 2016 | 57 | 0.030 |
Why?
|
Mucositis | 1 | 2017 | 108 | 0.030 |
Why?
|
Drug Repositioning | 1 | 2018 | 233 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2017 | 6305 | 0.030 |
Why?
|
Genome-Wide Association Study | 2 | 2015 | 12670 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2021 | 1176 | 0.030 |
Why?
|
Acrylamides | 1 | 2017 | 259 | 0.030 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2004 | 1074 | 0.030 |
Why?
|
Water | 1 | 2021 | 1410 | 0.030 |
Why?
|
Plasma | 1 | 1998 | 586 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1822 | 0.030 |
Why?
|
Anilides | 1 | 2017 | 411 | 0.030 |
Why?
|
K562 Cells | 1 | 2016 | 640 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2011 | 15915 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2016 | 3689 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2015 | 329 | 0.030 |
Why?
|
Receptors, Somatostatin | 1 | 2014 | 137 | 0.030 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2014 | 322 | 0.030 |
Why?
|
Physical Examination | 1 | 2000 | 1255 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1892 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2010 | 7844 | 0.030 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 353 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2022 | 2025 | 0.030 |
Why?
|
Infusions, Intraventricular | 1 | 2012 | 32 | 0.030 |
Why?
|
Antigens | 1 | 1999 | 1441 | 0.030 |
Why?
|
Delayed-Action Preparations | 3 | 2002 | 961 | 0.030 |
Why?
|
Acute Disease | 2 | 2010 | 7240 | 0.030 |
Why?
|
Drug Resistance | 1 | 2018 | 1594 | 0.030 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2014 | 254 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2013 | 197 | 0.030 |
Why?
|
Muscles | 1 | 1997 | 1567 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2015 | 597 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2019 | 956 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 3696 | 0.020 |
Why?
|
Vindesine | 1 | 2011 | 12 | 0.020 |
Why?
|
Neurons | 2 | 2023 | 9435 | 0.020 |
Why?
|
Area Under Curve | 2 | 2008 | 1636 | 0.020 |
Why?
|
Reference Standards | 1 | 2015 | 1005 | 0.020 |
Why?
|
Emergencies | 1 | 1998 | 1217 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2020 | 1375 | 0.020 |
Why?
|
Valine | 1 | 2013 | 408 | 0.020 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 1133 | 0.020 |
Why?
|
Diet | 1 | 2009 | 8047 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 2024 | 0.020 |
Why?
|
Steroids | 1 | 1996 | 929 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14676 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2021 | 3210 | 0.020 |
Why?
|
Ifosfamide | 1 | 2011 | 232 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1257 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1624 | 0.020 |
Why?
|
Multivariate Analysis | 3 | 2010 | 12058 | 0.020 |
Why?
|
Cell Lineage | 1 | 2019 | 2547 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2011 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3790 | 0.020 |
Why?
|
Frozen Sections | 1 | 2010 | 153 | 0.020 |
Why?
|
Audiometry, Pure-Tone | 1 | 2010 | 210 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2241 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1549 | 0.020 |
Why?
|
Thromboembolism | 1 | 1996 | 993 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 773 | 0.020 |
Why?
|
Massachusetts | 2 | 2014 | 8836 | 0.020 |
Why?
|
Risk Assessment | 4 | 2015 | 24013 | 0.020 |
Why?
|
Autopsy | 1 | 2013 | 1010 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2016 | 1490 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2013 | 5775 | 0.020 |
Why?
|
Niacinamide | 1 | 2011 | 413 | 0.020 |
Why?
|
Comparative Genomic Hybridization | 1 | 2010 | 473 | 0.020 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2011 | 251 | 0.020 |
Why?
|
Visual Acuity | 1 | 1999 | 2677 | 0.020 |
Why?
|
Meat Products | 1 | 2009 | 96 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1852 | 0.020 |
Why?
|
Molecular Biology | 1 | 2012 | 573 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2706 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 613 | 0.020 |
Why?
|
Monocytes | 1 | 2017 | 2570 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2015 | 1409 | 0.020 |
Why?
|
Blood Volume | 1 | 2009 | 547 | 0.020 |
Why?
|
Receptors, AMPA | 1 | 2009 | 335 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5750 | 0.020 |
Why?
|
Autophagy | 1 | 2015 | 1326 | 0.020 |
Why?
|
Endostatins | 1 | 2008 | 168 | 0.020 |
Why?
|
Integrins | 1 | 2012 | 834 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2816 | 0.020 |
Why?
|
Thrombospondins | 1 | 2008 | 194 | 0.020 |
Why?
|
Visual Perception | 1 | 2016 | 1385 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2013 | 1173 | 0.020 |
Why?
|
Diverticulitis | 1 | 2010 | 185 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4572 | 0.020 |
Why?
|
Cerebrospinal Fluid | 1 | 2010 | 544 | 0.020 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2009 | 446 | 0.020 |
Why?
|
Genome, Human | 1 | 2020 | 4423 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2014 | 1932 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3409 | 0.020 |
Why?
|
Mental Disorders | 1 | 2006 | 6818 | 0.020 |
Why?
|
Photons | 1 | 2010 | 589 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2007 | 211 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2022 | 4488 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9300 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2293 | 0.020 |
Why?
|
Metabolomics | 1 | 2015 | 1658 | 0.020 |
Why?
|
Learning | 1 | 2016 | 1739 | 0.020 |
Why?
|
Hemodynamics | 1 | 2016 | 4164 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2006 | 362 | 0.020 |
Why?
|
Enzyme Induction | 1 | 2006 | 452 | 0.020 |
Why?
|
Selection Bias | 1 | 2008 | 359 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10203 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15542 | 0.020 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2008 | 588 | 0.020 |
Why?
|
Speech Perception | 1 | 2010 | 508 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2003 | 11505 | 0.020 |
Why?
|
Attention | 1 | 2016 | 2394 | 0.020 |
Why?
|
Diet Surveys | 1 | 2009 | 1161 | 0.020 |
Why?
|
Nuclear Proteins | 2 | 2013 | 5781 | 0.020 |
Why?
|
Base Sequence | 2 | 2011 | 12404 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5478 | 0.020 |
Why?
|
Diffusion Tensor Imaging | 1 | 2015 | 2401 | 0.010 |
Why?
|
Neutropenia | 1 | 2010 | 885 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2015 | 2877 | 0.010 |
Why?
|
Societies, Medical | 1 | 2016 | 3923 | 0.010 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2010 | 781 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2015 | 3461 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2010 | 2898 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2008 | 877 | 0.010 |
Why?
|
Vaccination | 1 | 2016 | 3368 | 0.010 |
Why?
|
Carmustine | 1 | 2003 | 137 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2011 | 17598 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10758 | 0.010 |
Why?
|
Benzodiazepines | 1 | 2009 | 1134 | 0.010 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2005 | 550 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4308 | 0.010 |
Why?
|
Internationality | 1 | 2008 | 1000 | 0.010 |
Why?
|
Lectins | 1 | 2005 | 489 | 0.010 |
Why?
|
Adipokines | 1 | 2005 | 307 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4008 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2010 | 1116 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2013 | 2892 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14393 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8130 | 0.010 |
Why?
|
Models, Statistical | 1 | 2016 | 5077 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2006 | 1154 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2010 | 1182 | 0.010 |
Why?
|
Sample Size | 1 | 2005 | 841 | 0.010 |
Why?
|
Chronic Disease | 1 | 1996 | 9317 | 0.010 |
Why?
|
Arachnoiditis | 1 | 2001 | 9 | 0.010 |
Why?
|
Collagen | 1 | 2009 | 2635 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22129 | 0.010 |
Why?
|
Autoantigens | 1 | 2005 | 887 | 0.010 |
Why?
|
Anticoagulants | 1 | 1996 | 4795 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2006 | 1751 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 17349 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6565 | 0.010 |
Why?
|
Research | 1 | 2008 | 1975 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8303 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2003 | 620 | 0.010 |
Why?
|
Protein Kinases | 1 | 2006 | 1607 | 0.010 |
Why?
|
Decision Making | 1 | 2012 | 3925 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2001 | 429 | 0.010 |
Why?
|
United States | 2 | 2009 | 72337 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2008 | 5249 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3776 | 0.010 |
Why?
|
Infant | 1 | 2019 | 36164 | 0.010 |
Why?
|
Risk | 1 | 2009 | 9614 | 0.010 |
Why?
|
Epilepsy | 1 | 2012 | 3304 | 0.010 |
Why?
|
Cerebral Hemorrhage | 1 | 2007 | 2642 | 0.010 |
Why?
|
Spinal Cord Compression | 1 | 1998 | 234 | 0.010 |
Why?
|
Testis | 1 | 1999 | 781 | 0.010 |
Why?
|
Survivors | 1 | 2005 | 2369 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1999 | 4168 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2010 | 15845 | 0.010 |
Why?
|
Epitopes | 1 | 1999 | 2503 | 0.010 |
Why?
|
Health Status | 1 | 2005 | 4077 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1998 | 1474 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 13404 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1999 | 12743 | 0.000 |
Why?
|
Rats | 1 | 1999 | 23713 | 0.000 |
Why?
|